MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
NASDAQ
0.3933
-0.0108
-2.67%
Closed 19:48 07/17 EDT
OPEN
0.4125
PREV CLOSE
0.4041
HIGH
0.4200
LOW
0.3863
VOLUME
209.28K
TURNOVER
0
52 WEEK HIGH
1.950
52 WEEK LOW
0.1340
MARKET CAP
31.30M
P/E (TTM)
-1.2192
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCLI last week (0708-0712)?
Weekly Report · 3d ago
Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances into Enhanced Phase 3b ALS Trial
TipRanks · 6d ago
Brainstorm Cell Therptcs Price Target Announced at $2.00/Share by Maxim Group
Dow Jones · 6d ago
Brainstorm Cell Therptcs Raised to Buy From Hold by Maxim Group
Dow Jones · 6d ago
Maxim Group Upgrades Brainstorm Cell to Buy, Announces $2 Price Target
Benzinga · 6d ago
BRAINSTORM CELL THERAPEUTICS INC <BCLI.O>: MAXIM GROUP RAISES TO BUY FROM HOLD
Reuters · 07/11 11:40
IPO Roundup: Actuate Therapeutics, Autozi Internet, and more
IPO News IPO Roundup: Actuate Therapeutics, Autozi Internet, and more. Since the start of the year, the Renaissance IPO ETF has risen about 8.57%, underperforming the S&P 500 index. Upcoming IPOs/SPACs that are expected to be priced this week.
Seeking Alpha · 07/08 16:14
Weekly Report: what happened at BCLI last week (0701-0705)?
Weekly Report · 07/08 11:39
More
About BCLI
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Webull offers Brainstorm Cell Therapeutics Inc stock information, including NASDAQ: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.